

LEMTRADA REMS PATIENT AUTHORIZATION AND BASELINE LAB FORM

Please submit this form online at www.LemtradaREMS.com or fax this completed form to the LEMTRADA REMS at 1-855-557-2478

This form must be completed within 30 days prior to the first infusion date of each LEMTRADA® (alemtuzumab) patient's treatment course.

^{*}Indicates a mandatory field.

PRESCRIBER INFORMATION (PLEASE PRINT)			
Name (Last, First)*		Office Phone Number*	
Address*			
City*	State	*	ZIP Code*
Prescriber LEMTRADA REMS Identification Number	•		

PATIENT INFORMATION (PLEASE PRINT)

Name (Last, First)*

Patient LEMTRADA REMS Identification Number*

Date of Birth (MM/DD/YYYY)*

AUTHORIZATION AND BASELINE LABS

Do you authorize LEMTRADA treatment for the above-referenced patient?* O Yes O No

Do you attest that required baseline laboratory testing has been completed prior to LEMTRADA treatment and within 30 days of the patient's first infusion?* O Yes O No

PRESCRIPTION INFORMATION

Check one* O Initial course (1 vial [12 mg/day]) X 5 consecutive days O Subsequent course (1 vial [12 mg/day]) X 3 consecutive days

Total number of vials:	
Total number of vials:	

SIGNATURE

Prescriber Signature*

Date*

Please submit this form online at www.LemtradaREMS.com or fax this completed form to the LEMTRADA REMS at 1-855-557-2478 If you have any questions regarding the LEMTRADA REMS, call 1-855-676-6326

©2022 Genzyme Corporation. All rights reserved.

Lemtrada and Sanofi are registered in U.S. Patent and Trademark Office. US.MS.LEM.14.11.002-v6-07/2022

sanofi